



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/986,725	11/09/2001	Bo Skaaning Jensen	2815-0183P	5880
2292	7590	08/09/2002	EXAMINER	
BIRCH STEWART KOLASCH & BIRCH PO BOX 747 FALLS CHURCH, VA 22040-0747			FORD, JOHN M	
ART UNIT	PAPER NUMBER			
1624				
DATE MAILED: 08/09/2002				

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/988725	Applicant(s)
Examiner <i>J.M. Foss</i>	Group Art Unit

—The MAILING DATE of this communication appears on the cover sheet beneath the correspondence address—

Period for Response

A SHORTENED STATUTORY PERIOD FOR RESPONSE IS SET TO EXPIRE **ONE** MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a response be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for response specified above is less than thirty (30) days, a response within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for response is specified above, such period shall, by default, expire SIX (6) MONTHS from the mailing date of this communication .
- Failure to respond within the set or extended period for response will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).

Status

- Responsive to communication(s) filed on _____.
- This action is **FINAL**.
- Since this application is in condition for allowance except for formal matters, **prosecution as to the merits is closed** in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

- Claim(s) 1 - 25 is/are pending in the application.
- Of the above claim(s) _____ is/are withdrawn from consideration.
- Claim(s) _____ is/are allowed.
 - Claim(s) _____ is/are rejected.
 - Claim(s) _____ is/are objected to.
- Claim(s) 1 - 25 are subject to restriction or election requirement.

Application Papers

- See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.
- The proposed drawing correction, filed on _____ is approved disapproved.
- The drawing(s) filed on _____ is/are objected to by the Examiner.
- The specification is objected to by the Examiner.
- The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119 (a)-(d)

- Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
- All Some* None of the CERTIFIED copies of the priority documents have been received.
- received in Application No. (Series Code/Serial Number) _____.
- received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

*Certified copies not received: _____.

Attachment(s)

- Information Disclosure Statement(s), PTO-1449, Paper No(s). _____
- Interview Summary, PTO-413
- Notice of References Cited, PTO-892
- Notice of Informal Patent Application, PTO-152
- Notice of Draftsperson's Patent Drawing Review, PTO-948
- Other _____

Office Action Summary

Art Unit: 1624

The claims in the application are claims 1--25.

"Use" claims are not proper in this country.

The claims need be expressed as a method of treating, in order to permit assignment of the application to a particular Examiner.

The claims violate 35 U.S.C. 101 and 35 U.S.C. 112, since they are drafted in terms of use. See Clinical Products vs. Brenner, 255 F. Supp. 151; 149 USPQ 475 (D.C. District Columbia 1966).

Having selective IK_{Ca} modulatory activity is not one use per PCT Rule 13.2 and 37 CFR 1.475.

The agreement to Examine, one use of the compounds does not extend to additional active ingredients.


Therefore, restriction is required between (Group I) claims 1--19, and (Group II) claims 20 and 21 which recite an additional active ingredient, and (Group III) claims 22--25 which do not recite a particular active ingredient.

Assuming Group I is elected, i.e. claims 1--19. Applicants need elect a particular utility from the list in claim 19, for instance, and express the claim, as a method of treating, including one active ingredient .

37 CFR 1.499 requires an election and response.

John M. Ford:jmr

August 7, 2002



JOHN M. FORD
PRIMARY EXAMINER
Aug 7 2002 Art Unit 1624